Munich-based inveox provides Artificial Intelligence supported cancer diagnosis. Following its expansion into Germany, Austria, and Switzerland (DACH region), it continues to grow as the heathtech startup opened a subsidiary office in Krakow, Poland.
Now, the company has secured €17 million from its existing investors to improve cancer diagnosis. With this investment, inveox aims to begin series-level production of AI-supported automation system to make cancer diagnosis more reliable and faster.
Improves cancer diagnosis
Founded in 2017 by Maria Sievert and Dominik Sievert, inveox aims to help people suffering from cancer by improving the reliability of cancer diagnosis. They founded the startup with the intention to bring technologies including digitisation, Artificial Intelligence, and automation into the world of histopathology. With these processes, cancer diagnosis is not only faster but also safer. It improves both the arrival and testing of tissue samples in a lab.
Connects pathology labs
This German startup develops systems to automate, digitise and connect pathology laboratories. It wants to ensure cancer diagnosis is profitable and efficient for laboratories. Also, inveox is planning to unlock the potential of personalised diagnostics with the help of Artificial Intelligence and big data.